MSI2 and chronic myelogenous leukemia, BCR-ABL1 positive: MSI2 is also highly upregulated during human CML progression, and its expression serves as an early indicator of poor prognosis not only in leukemias but also in solid cancers like lung cancer (Makhov et al., 2021).